Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non Operating Investment Income (2016 - 2023)

Ironwood Pharmaceuticals' Non Operating Investment Income history spans 9 years, with the latest figure at $19000.0 for Q1 2023.

  • On a quarterly basis, Non Operating Investment Income fell 97.4% to $19000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $19000.0, a 89.56% decrease, with the full-year FY2023 number at $19000.0, down 89.56% from a year prior.
  • Non Operating Investment Income hit $19000.0 in Q1 2023 for Ironwood Pharmaceuticals, up from -$18000.0 in the prior quarter.
  • Over the last five years, Non Operating Investment Income for IRWD hit a ceiling of $4.5 million in Q4 2019 and a floor of -$4.8 million in Q3 2019.
  • Historically, Non Operating Investment Income has averaged -$240176.5 across 5 years, with a median of -$18000.0 in 2022.
  • Biggest five-year swings in Non Operating Investment Income: skyrocketed 199.7% in 2019 and later plummeted 710.95% in 2021.
  • Tracing IRWD's Non Operating Investment Income over 5 years: stood at $4.5 million in 2019, then crashed by 90.7% to $420000.0 in 2020, then plummeted by 710.95% to -$2.6 million in 2021, then surged by 99.3% to -$18000.0 in 2022, then surged by 205.56% to $19000.0 in 2023.
  • Business Quant data shows Non Operating Investment Income for IRWD at $19000.0 in Q1 2023, -$18000.0 in Q4 2022, and $151000.0 in Q3 2022.